These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37043830)

  • 41. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.
    Lemoine M; Assoumou L; De Wit S; Girard PM; Valantin MA; Katlama C; Necsoi C; Campa P; Huefner AD; Schulze Zur Wiesch J; Rougier H; Bastard JP; Stocker H; Mauss S; Serfaty L; Ratziu V; Menu Y; Schlue J; Behrens G; Bedossa P; Capeau J; Ingiliz P; Costagliola D;
    J Acquir Immune Defic Syndr; 2019 Apr; 80(4):e86-e94. PubMed ID: 30570529
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People With Diabetes Versus People Without Diabetes: A Multicenter Study.
    Huang DQ; Wilson LA; Behling C; Kleiner DE; Kowdley KV; Dasarathy S; Amangurbanova M; Terrault NA; Diehl AM; Chalasani N; Neuschwander-Tetri BA; Sanyal AJ; Tonascia J; ; Loomba R
    Gastroenterology; 2023 Aug; 165(2):463-472.e5. PubMed ID: 37127100
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH.
    Ampuero J; Aller R; Gallego-Durán R; Crespo J; Calleja JL; García-Monzón C; Gómez-Camarero J; Caballería J; Lo Iacono O; Ibañez L; García-Samaniego J; Albillos A; Francés R; Fernández-Rodríguez C; Diago M; Soriano G; Andrade RJ; Latorre R; Jorquera F; Morillas RM; Escudero D; Estévez P; Guerra MH; Augustín S; Banales JM; Aspichueta P; Benlloch S; Rosales JM; Salmerón J; Turnes J; Romero Gómez M;
    J Hepatol; 2020 Jul; 73(1):17-25. PubMed ID: 32147361
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options.
    Younossi Z; Stepanova M; Sanyal AJ; Harrison SA; Ratziu V; Abdelmalek MF; Diehl AM; Caldwell S; Shiffman ML; Schall RA; McColgan B; Subramanian GM; Myers RP; Muir A; Afdhal NH; Bosch J; Goodman Z
    J Hepatol; 2018 Dec; 69(6):1365-1370. PubMed ID: 30144554
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Assessment of liver fibrosis using non-invasive screening tools in individuals with diabetes mellitus and metabolic syndrome.
    Shaji N; Singhai A; Joshi R
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443467
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study.
    Harrison SA; Ratziu V; Boursier J; Francque S; Bedossa P; Majd Z; Cordonnier G; Sudrik FB; Darteil R; Liebe R; Magnanensi J; Hajji Y; Brozek J; Roudot A; Staels B; Hum DW; Megnien SJ; Hosmane S; Dam N; Chaumat P; Hanf R; Anstee QM; Sanyal AJ
    Lancet Gastroenterol Hepatol; 2020 Nov; 5(11):970-985. PubMed ID: 32763196
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Noninvasive identification of probable fibrotic nonalcoholic steatohepatitis across the spectrum of glucose tolerance in the United States.
    Ciardullo S; Carbone M; Invernizzi P; Perseghin G
    Diabetes Res Clin Pract; 2023 May; 199():110679. PubMed ID: 37094749
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis.
    Pelusi S; Cespiati A; Rametta R; Pennisi G; Mannisto V; Rosso C; Baselli G; Dongiovanni P; Fracanzani AL; Badiali S; Maggioni M; Craxi A; Fargion S; Prati D; Nobili V; Bugianesi E; Romeo S; Pihlajamaki J; Petta S; Valenti L
    Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2310-2319.e6. PubMed ID: 30708111
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ability of Cytokeratin-18 Fragments and FIB-4 Index to Diagnose Overall and Mild Fibrosis Nonalcoholic Steatohepatitis in Japanese Nonalcoholic Fatty Liver Disease Patients.
    Kobayashi N; Kumada T; Toyoda H; Tada T; Ito T; Kage M; Okanoue T; Kudo M
    Dig Dis; 2017; 35(6):521-530. PubMed ID: 29040984
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic Steatohepatitis Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-Analysis.
    Andersson A; Kelly M; Imajo K; Nakajima A; Fallowfield JA; Hirschfield G; Pavlides M; Sanyal AJ; Noureddin M; Banerjee R; Dennis A; Harrison S
    Clin Gastroenterol Hepatol; 2022 Nov; 20(11):2451-2461.e3. PubMed ID: 34626833
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Transient elastography for the prevalence of non-alcoholic fatty liver disease in patients with type 2 diabetes: Evidence from the CORDIAL cohort study.
    Alfadda AA; Sherbeeni SM; Alqutub AN; Aldosary AS; Aldaghri NM; Taylor-Robinson SD; Alqahtani SA; Gul R; Almaghamsi AM
    Saudi J Gastroenterol; 2022; 28(6):426-433. PubMed ID: 35645140
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity.
    Pavlides M; Banerjee R; Tunnicliffe EM; Kelly C; Collier J; Wang LM; Fleming KA; Cobbold JF; Robson MD; Neubauer S; Barnes E
    Liver Int; 2017 Jul; 37(7):1065-1073. PubMed ID: 27778429
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Non-alcoholic fatty liver disease in pediatric type 2 diabetes: Metabolic and histologic characteristics in 38 subjects.
    Newfield RS; Graves CL; Newbury RO; Schwimmer JB; Proudfoot JA; Say DS; Feldstein AE
    Pediatr Diabetes; 2019 Feb; 20(1):41-47. PubMed ID: 30467936
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort.
    Harrison SA; Gawrieh S; Roberts K; Lisanti CJ; Schwope RB; Cebe KM; Paradis V; Bedossa P; Aldridge Whitehead JM; Labourdette A; Miette V; Neubauer S; Fournier C; Paredes AH; Alkhouri N
    J Hepatol; 2021 Aug; 75(2):284-291. PubMed ID: 33746083
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness.
    Liebig S; Stoeckmann N; Geier A; Rau M; Schattenberg JM; Bahr MJ; Manns MP; Jaeckel E; Schulze-Osthoff K; Bantel H
    Clin Transl Gastroenterol; 2019 Aug; 10(8):e00066. PubMed ID: 31397685
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High Prevalence of Advanced Liver Fibrosis Assessed by Transient Elastography Among U.S. Adults With Type 2 Diabetes.
    Ciardullo S; Monti T; Perseghin G
    Diabetes Care; 2021 Feb; 44(2):519-525. PubMed ID: 33303638
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prevalence and Specific Manifestations of Non-alcoholic Fatty Liver Disease (NAFLD) and Diabetes Mellitus Type 2 Association in a Moroccan Population: A Cross-sectional Study.
    Assarrar I; Messaoudi N; Ongoth FEM; Abdellaoui W; Malki A; Rouf S; Abda N; Ismaili Z; Latrech H
    Rev Diabet Stud; 2022 Sep; 18(3):140-145. PubMed ID: 36309775
    [No Abstract]   [Full Text] [Related]  

  • 58. MR elastography is effective for the non-invasive evaluation of fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease.
    Costa-Silva L; Ferolla SM; Lima AS; Vidigal PVT; Ferrari TCA
    Eur J Radiol; 2018 Jan; 98():82-89. PubMed ID: 29279175
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients.
    Ong JP; Elariny H; Collantes R; Younoszai A; Chandhoke V; Reines HD; Goodman Z; Younossi ZM
    Obes Surg; 2005 Mar; 15(3):310-5. PubMed ID: 15826462
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials.
    Davison BA; Harrison SA; Cotter G; Alkhouri N; Sanyal A; Edwards C; Colca JR; Iwashita J; Koch GG; Dittrich HC
    J Hepatol; 2020 Dec; 73(6):1322-1332. PubMed ID: 32610115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.